File

Lettuce Financial Launches Solution to Democratize Accounting and Tax Services for Solopreneurs; Announces $6 Million in Seed Funding

Retrieved on: 
Wednesday, March 6, 2024

As a result, solopreneurs making $100,000 or more are overpaying their taxes by approximately $15,000 or more per year.

Key Points: 
  • As a result, solopreneurs making $100,000 or more are overpaying their taxes by approximately $15,000 or more per year.
  • Handles all aspects of a solopreneur's taxes and accounting, from LLC and S-Corp setup and managing IRS requirements to preparing annual tax forms.
  • In addition to launching their solution, Lettuce announced $6 million in funding led by Zeev Ventures.
  • Lettuce will provide a complimentary 2023 tax return for solopreneurs to use for filing or as a second opinion in comparison with their existing tax service.

Kelso Technologies Inc. Announces Intention to Delist From NYSE American

Retrieved on: 
Tuesday, March 5, 2024

VANCOUVER, British Columbia and BONHAM, Texas, March 05, 2024 (GLOBE NEWSWIRE) -- Kelso Technologies Inc. (“Kelso” or the “Company”), (TSX: KLS), (NYSE American: KIQ) today announced that it has notified the NYSE American (“NYSE American”) of its intention to voluntarily delist its common shares (“Shares”) from the NYSE American.

Key Points: 
  • VANCOUVER, British Columbia and BONHAM, Texas, March 05, 2024 (GLOBE NEWSWIRE) -- Kelso Technologies Inc. (“Kelso” or the “Company”), (TSX: KLS), (NYSE American: KIQ) today announced that it has notified the NYSE American (“NYSE American”) of its intention to voluntarily delist its common shares (“Shares”) from the NYSE American.
  • The Shares will continue to trade on the Toronto Stock Exchange (“TSX”).
  • After careful consideration, the Company has evaluated the benefits and costs of continuing its listing on NYSE American and has concluded that it is appropriate to voluntarily delist from the NYSE American at this time.
  • The Company does not expect to seek to list its shares on another U.S. national securities exchange or U.S. quotation system.

BridgeBio Pharma Announces Proposed Public Offering of Common Stock

Retrieved on: 
Monday, March 4, 2024

PALO ALTO, Calif., March 04, 2024 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio”), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, announced today that it has commenced an underwritten public offering of $250 million of shares of its common stock.

Key Points: 
  • PALO ALTO, Calif., March 04, 2024 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio”), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, announced today that it has commenced an underwritten public offering of $250 million of shares of its common stock.
  • BridgeBio also intends to grant the underwriters a 30-day option to purchase up to an additional $37.5 million of shares of its common stock.
  • All of the shares in the proposed offering are to be sold by BridgeBio.
  • The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the proposed offering.

American Hotel Income Properties REIT LP Files 2023 Annual Financial Statements and Management’s Discussion and Analysis

Retrieved on: 
Monday, March 4, 2024

VANCOUVER, British Columbia, March 04, 2024 (GLOBE NEWSWIRE) -- American Hotel Income Properties REIT LP (“AHIP”, or the “Company”) (TSX: HOT.UN, TSX: HOT.U, TSX: HOT.DB.V), today announced the filing with securities regulators in Canada of its audited consolidated financial statements for the years ended December 31, 2023 and 2022 (the “Financial Statements”), and management’s discussion and analysis for the years ended December 31, 2023 and 2022 (“MD&A”).

Key Points: 
  • VANCOUVER, British Columbia, March 04, 2024 (GLOBE NEWSWIRE) -- American Hotel Income Properties REIT LP (“AHIP”, or the “Company”) (TSX: HOT.UN, TSX: HOT.U, TSX: HOT.DB.V), today announced the filing with securities regulators in Canada of its audited consolidated financial statements for the years ended December 31, 2023 and 2022 (the “Financial Statements”), and management’s discussion and analysis for the years ended December 31, 2023 and 2022 (“MD&A”).

VENTYX ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Ventyx Biosciences, Inc. and Encourages Investors to Contact the Firm

Retrieved on: 
Monday, March 4, 2024

Investors have until April 30, 2024 to apply to the Court to be appointed as lead plaintiff in the lawsuit.

Key Points: 
  • Investors have until April 30, 2024 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
  • Ventyx is a clinical-stage biopharmaceutical company that develops small-molecule product candidates to address a range of inflammatory diseases.
  • In addition, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company's business, operations, and prospects.
  • On November 6, 2023, during after-market hours, Ventyx issued a press release announcing results from the Phase 2 SERENITY Trial.

Tarsus Announces Pricing of $100.0 Million Public Offering

Retrieved on: 
Friday, March 1, 2024

In addition, Tarsus has granted the underwriters a 30-day option to purchase up to an additional 468,750 shares of its common stock at the public offering price, less underwriting discounts and commissions.

Key Points: 
  • In addition, Tarsus has granted the underwriters a 30-day option to purchase up to an additional 468,750 shares of its common stock at the public offering price, less underwriting discounts and commissions.
  • The gross proceeds from the offering, before deducting underwriting discounts and commissions and other estimated offering expenses payable by Tarsus, are expected to be approximately $100.0 million, excluding any exercise of the underwriters’ option to purchase additional shares.
  • The offering is expected to close March 5, 2024, subject to the satisfaction of customary closing conditions.
  • Goldman Sachs & Co. LLC, BofA Securities, Guggenheim Securities, LLC and Oppenheimer & Co. are acting as joint book-running managers for the offering.

Tarsus Announces Proposed $100.0 Million Public Offering

Retrieved on: 
Thursday, February 29, 2024

Tarsus also intends to grant the underwriters a 30-day option to purchase up to an additional $15.0 million of shares of its common stock offered in the proposed offering.

Key Points: 
  • Tarsus also intends to grant the underwriters a 30-day option to purchase up to an additional $15.0 million of shares of its common stock offered in the proposed offering.
  • All securities in the proposed offering are to be sold by Tarsus.
  • The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
  • Goldman Sachs & Co. LLC, BofA Securities, Guggenheim Securities, LLC and Oppenheimer & Co. are acting as joint book-running managers for the offering.

Capricor Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Thursday, February 29, 2024

Further, Capricor will receive a meaningful mid-range double-digit revenue share of product revenue under the terms of this Agreement.

Key Points: 
  • Further, Capricor will receive a meaningful mid-range double-digit revenue share of product revenue under the terms of this Agreement.
  • Next steps for Cohort A: plan to report top-line data in the fourth quarter of 2024.
  • Revenues for the fourth quarter of 2023 were approximately $12.1 million compared with approximately $1.0 million for the fourth quarter of 2022.
  • Operating expenses: Total operating expenses for the fourth quarter of 2023 were approximately $13.2 million compared with approximately $9.0 million for the fourth quarter of 2022.

Editas Medicine Announces Fourth Quarter and Full Year 2023 Results and Business Updates

Retrieved on: 
Wednesday, February 28, 2024

CAMBRIDGE, Mass., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today reported financial results for the fourth quarter and full year 2023 and provided business updates.

Key Points: 
  • CAMBRIDGE, Mass., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today reported financial results for the fourth quarter and full year 2023 and provided business updates.
  • In 2023, Editas Medicine strengthened and focused its discovery organization to build an in vivo gene editing pipeline.
  • Editas Medicine plans to participate in the following investor events:
    The Editas Medicine management team will host a conference call and webcast today at 8:00 a.m.
  • ET to provide and discuss a corporate update and financial results for the fourth quarter and full year of 2023.

Theratechnologies Receives Refusal to File Letter for Trogarzo® Intramuscular Method of Administration sBLA from FDA

Retrieved on: 
Tuesday, February 27, 2024

MONTREAL, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that the United States Food and Drug Administration (FDA) has issued a refusal to file letter (RTF) regarding the Company’s supplemental Biologics License Application (sBLA) for an intramuscular (IM) method of administration for the maintenance dose of Trogarzo® (ibalizumab-uiyk).

Key Points: 
  • MONTREAL, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that the United States Food and Drug Administration (FDA) has issued a refusal to file letter (RTF) regarding the Company’s supplemental Biologics License Application (sBLA) for an intramuscular (IM) method of administration for the maintenance dose of Trogarzo® (ibalizumab-uiyk).
  • The sBLA filing was announced on January 2, 2024.
  • Upon preliminary review, the FDA determined that the sBLA was not sufficiently complete to permit a substantive review.
  • The RTF states that the sBLA did not contain the data required to establish the pharmacokinetic bridge between the IM and the intravenous infusion route of administration of Trogarzo®.